Engraftment of wild-type alveolar type II epithelial cells in surfactant protein C deficient mice

Area of Science:

• Pulmonary Medicine
• Regenerative Medicine
• Genetics

Background:

• Childhood interstitial lung disease (chILD) due to surfactant deficiency causes severe respiratory issues and lung fibrosis.
• Current treatments are limited, with lung transplantation facing organ shortages, especially for pediatric patients.

Purpose of the Study:

• To investigate cell therapy as a potential treatment for chILD by using a mouse model.
• To demonstrate the feasibility of engrafting functional alveolar epithelial type II (ATII) cells to restore lung function.

Main Methods:

• Utilized Sftpc knockout mice, a model mimicking human chILD with surfactant deficiency.
• Administered low-dose bleomycin to condition the lungs for cell engraftment.
• Transplanted wild-type ATII cells into the Sftpc-/- mice.

Main Results:

• Sftpc-/- mice exhibited age-dependent chronic lung disease and increased sensitivity to bleomycin.
• Successful engraftment of wild-type ATII cells was achieved post-bleomycin conditioning.
• Transplanted cells produced surfactant protein C (SPC) and mitigated bleomycin-induced lung injury for up to two months.

Conclusions:

• Partial replacement of mutant ATII cells with functional cells can promote lung repair in a chILD mouse model.
• This study provides proof-of-principle for ATII cell-based therapy in treating surfactant deficiency-related chILD.
• Further research into gene-corrected cell therapy could offer a curative approach for pediatric lung disease.